$2.53
8.12%
NYSE, Sep 17, 04:12 pm EDT. Closed.
ISIN
US36870H1032
Symbol
GNLX

Genelux Stock price

$2.53
-0.17 6.30% 1M
-0.09 3.44% 6M
-1.83 41.97% YTD
-1.38 35.29% 1Y
-22.85 90.03% 3Y
-3.47 57.83% 5Y
-3.47 57.83% 10Y
-3.47 57.83% 20Y
NYSE, Closing price Thu, Sep 17 2026
+0.19 8.12%
ISIN
US36870H1032
Symbol
GNLX
Industry

Is Genelux a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$105.9m
Enterprise Value
$87.2m
Net debt
positive
Cash
$18.7m
Shares outstanding
44.7m
Valuation (TTM | estimate)
P/E
negative
P/S
10,587.4 | -
EV/Sales
8,720.4 | -
EV/FCF
negative
P/B
6.6
Financial Health
Equity Ratio
60.7%
Return on Equity
-278.5%
ROCE
-200.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.0k | $0.0
EBITDA
$-36.3m
EBIT
$-36.4m
Net Income
$-35.6m
Free Cash Flow
$-28.7m
Growth (TTM | estimate)
Revenue
- | -100.0%
EBITDA
-14.5%
EBIT
-14.1%
Net Income
-17.1%
Free Cash Flow
-24.8%
Margin
Gross
-
EBITDA
-453,500.0%
EBIT
-455,275.0%
Net
-444,950.0%
Free Cash Flow
-358,537.5%
More
EPS
$-0.8
FCF per Share
$-0.6
Short interest
8.6%
Employees
26
Rev per Employee
$0.0

Genelux Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Genelux forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Genelux forecast:

Buy
91%
Hold
9%

Financial data from Genelux

Jun '26
+/-
%
0.01 0.01
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
12% 12%
137,500%
- Research and Development Expense 23 23
42% 42%
226,800%
-36 -36
14% 14%
-362,800%
- Depreciation and Amortization 0.14 0.14
42% 42%
1,400%
EBIT (Operating Income) EBIT -36 -36
14% 14%
-364,220%
Net Profit -36 -36
17% 17%
-356,000%

In millions USD.

Don't miss a Thing! We will send you all news about Genelux directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genelux Stock News

Neutral
GlobeNewsWire
8 days ago
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux , exceeding the reduction achieved following first-line therapy --
Neutral
GlobeNewsWire
about one month ago
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial  of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026 --
Neutral
GlobeNewsWire
3 months ago
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
More Genelux News

Company Profile

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Head office United States
CEO Mr. Zindrick
Employees 26
Founded 2001
Website genelux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today